anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hypoglycemia (from insulin and liraglutide) and gastrointestinal adverse reactions (from liraglutide) may develop if a patient is dosed with more XULTOPHY 100/3.6 than required. 

An excess of insulin-containing products like XULTOPHY 100/3.6 relative to food intake, energy expenditure, or both may lead to severe and sometimes prolonged and life-threatening hypoglycemia and hypokalemia [see Warnings and Precautions (5.6, 5.10)]. Mild episodes of hypoglycemia usually can be treated with oral glucose. Lowering the drug dosage, and adjustments in meal patterns, or exercise may be needed. More severe episodes of hypoglycemia with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon for emergency use or concentrated intravenous glucose. After apparent clinical recovery from hypoglycemia, continued observation and additional carbohydrate intake may be necessary to avoid reoccurrence of hypoglycemia. Hypokalemia must be corrected appropriately. 

Overdoses have been reported in clinical trials and postmarketing use of liraglutide, one of the components of XULTOPHY 100/3.6. Effects have included severe nausea and severe vomiting. In the event of overdosage, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
The present invention provides a new medical agent that inhibits aggregation of amyloid-β causing Alzheimer's disease and the like.　The amyloid-β aggregation inhibitor according to the present invention is characterized by including a peptide having an amino acid sequence represented by SEQ ID NO. 1 and/or a peptide having an amino acid sequence represented by SEQ ID NO. 2. The pharmaceutical composition for amyloid-β aggregation diseases is characterized by including a peptide having an amino acid sequence represented by SEQ ID NO. 1 and/or a peptide having an amino acid sequence represented by SEQ ID NO. 2. SEQ ID NO. 1: GSGNR
SEQ ID NO. 2: GSGFK
The invention provides a novel vehicle for vaccination, in particular peptide vaccination. The new vehicle has been termed an exosome. Exosomes are vesicles derived from MHC class II enriched compartments in antigen presenting cells.  The exosomes possess MHC II and/or MHC I molecules at their surface and possibly peptides derived from processed antigens in said MHC's. Thus the exosome is a perfect vaccination vehicle in that it presents the peptide in a natural setting. The peptides present in the exosome in the MHC molecule may be processed by the antigen presenting cell from which the exosome is derived.  Empty MHC molecules on exosomes may also be loaded with peptides afterwards.
Fructans are commonly used as dietary fibre supplements for their ability to promote the growth of beneficial gut microbes. However, fructan consumption has been associated with various dosage-dependent side effects. We characterised side effects in an exploratory analysis of a randomised trial in healthy adults (n = 40) who consumed 18 g/day inulin or placebo. We found that individuals weighing more or habitually consuming higher fibre exhibited the best tolerance. Furthermore, we identified associations between gut microbiome composition and host tolerance. Specifically, higher levels of Christensenellaceae R-7 group were associated with gastrointestinal discomfort, and a machine-learning-based approach successfully predicted high levels of flatulence, with [Ruminococcus] torques group and (Oscillospiraceae) UCG-002 sp. identified as key predictive taxa. These data reveal trends that can help guide personalised recommendations for initial inulin dosage. Our results support prior ecological findings indicating that fibre supplementation has the greatest impact on individuals whose baseline fibre intake is lowest.
The invention relates to a kaurane compound, and provides a preparation method and a purpose of the compound. The disclosed kaurane compound is a white powdery matter with a chemical name of ent-kauran-3beta,16beta-17-,19-tetrol, and a molecular formula of C20H34O4. Smallanthus sonchifolius leaves are processed through a rough extraction. The crude extract is processed through a macroporous resin column chromatography, a silica gel column chromatography and a reversed-phase C18 column chromatography, such that a kaurane compound crude product is obtained. A high-efficiency liquid-phase preparation is then carried out, such that a kaurane compound is obtained. Through extraction and separation, the new kaurane compound is obtained from smallanthus sonchifolius leaves. The compound can effectively inhibit the activity of alpha-glucosidase. 1.6mg/ml of the compound contributes in achieving an alpha-glucosidase inhibition rate of about 70%. Therefore, with a good blood glucose reducing effect and a good anti-diabetes effect, the compound can be widely applied in the preparation of medicines against uretic diseases, and has potentials to be exploited in the production of anti-diabetes medicines.
An athletic strap includes a glove portion including a plantar aspect, a dorsal aspect, and a cavity defined between the plantar and dorsal aspects. The cavity is configured to receive at least part of a hand or a foot of a user. The glove portion further includes a first opening at one end of the glove portion and a second opening at another end of the glove portion. The first and second openings provide ingress to or egress from the cavity. The glove portion further includes a strip extending between the plantar and dorsal aspects. The strip is adjacent to the second opening. The glove portion further includes a first indicium disposed on the plantar aspect. The first indicium extends along a first axis. The first axis is coincident with a portion of the strip.
1502774 Vaccines containing liposomes NATIONAL RESEARCH DEVELOPMENT CORP 19 June 1975 [25 June 1974] 28131/74 Heading A5B Immunising preparations comprise an antigenic material and negatively charged liposomes. The antigenic material may be bacterial antigen (e.g. diphtheria or tetanus toxoid) or a viral antigen (e.g. influenza virus). Examples specify the presence of mycobacterium tuberculosis (killed) and Bordetella pertussis. The liposomes may be formed with egg lecithin, and the negative charge may be achieved by addition of phosphatidic acid or dicetyl phosphate.
NEW MATERIAL:An alkaloid expressed by formula I. USE:A medicine and antihypertensive agent having hypotensive action of long duration. PREPARATION:FUNBOI (dried radix of Stephania tetrandra S. Moore) which is a crude drug originated from a root of the Stephania tetrandra S. Moore belonging to the family Menispermaceae is extracted with water, alcohols or a mixed solvent of water with alcohols. The solvent is then removed to give a residue, which is subsequently dissolved in the above-mentioned mixed solvent and distributed with an organic solvent to remove fat-soluble components. The resultant substance is dissolved in aqueous ammonia at pH 9 and then extracted with chloroform to provide an aqueous ammonia extract and chloroform extract essences. The chloroform extract essence is subsequently subjected to column chromatography several times using alumina, etc., as a carrier to give fangchinoline expressed by formula II, which is then ethylated with an ethylating agent, e.g. phenyltriethylammonium, etc., in a solvent. After the reaction, the solvent is distilled away and the residue is subjected to column chromatography using alumina, etc., as a carrier to afford the aimed compound expressed by formula I.
The invention relates to a food therapy preparation for preventing and treating diabetes based on the theories of preventive treatment of disease and medicine food homology, which is characterized by comprising the effective ingredients of the following raw materials in weight ratio: 4-6 dark plum fruits, 6-8 fragrant solomonseal rhizome, 14-16 Chinese yam, 4-6 barbary wolfberry fruits, 6-8 hawthorn and 14-16 fresh reed roots. The prescription of the food therapy preparation is based on the theory of preventive treatment of disease, and the food therapy preparation is prepared from a sufficient amount of effective ingredients. Although the food therapy preparation is not a medicine, the actions of the medicine can be exerted. The food therapy preparation not only can greatly limit the occurrence and the development of the diabetes, but also can save a great amount of medical resources and investments for China simultaneously. People can conveniently and correctly select the food therapy preparation in a pertinence way according to early symptoms per se to prevent the possible occurrence of the diabetes, and thus, the purposes of disease prevention and body building are achieved. The food therapy preparation can be directly taken according to a certain amount, and can also be eaten together with foods and drinks as an additive of the foods and the drinks.
Lacerations are typically closed with sutures, staples, tissue adhesives, or bandages. These methods come with several limitations, however. Sutures and staples can be painful, cause inflammation that can lead to scarring, and require return clinic visits for their removal. Tissue adhesives cannot be used to close wounds under tension, can be associated with inflammation, and carry a risk of wound dehiscence. Bandages are also only useful for closing superficial wounds under low tension. Therefore, there is a need for improved products to close wounds associated with laceration repair.

The current study will use a prospective randomized controlled design to compare the use of sutures to microMend® to treat lacerations among children 7-17 years. Performance of sutures and microMend® will be assessed by investigators, providers and subjects. Participants will be randomized 1:1 between closure of lacerations with microMend® or sutures. Results from this study will help gather further information on the use of microMend® to close wounds in the pediatric population.
NEW MATERIAL:A peptide expressed by the formula. USE:A measuring reagent for antibodies having specificity for human T cell leukemic virus type II (HTLV-II)-related antigens and a diagnostic agent for infection with the HTLV-II. PREPARATION:For example, styrene-divinylbenzene copolymer having 4-[N-alpha-(tert-butoxycarbonyl)-L-leucyloxymethyl]phenylacetamidomethyl groups is used as an insoluble support and an amino acid having protected alpha-amino group and functional group in the side chain is successively bound from the side of the C-terminal bond according to an amino acid sequence of the peptide by a solid-phase synthetic method. The alpha-amino-protecting group is then removed. The aforementioned operation is repeated to synthesize a peptide chain, which is then treated with hydrogen fluoride. Elimination of the resultant peptide from the resin and removal of all the protecting groups are carried out. The obtained peptide is subsequently purified by reversed phase high-performance liquid chromatography to afford the objective peptide expressed by the formula.
Obstructive sleep apnea (OSA) is one of the most common complications of obesity, resulting in excessive sleepiness and daytime functional impairment as well as acting synergistically with obesity in predisposing to hypertension, insulin resistance, diabetes, cardiovascular disease, and stroke. The current first line treatment for moderate to severe OSA, nasal continuous positive airway pressure (CPAP) is extremely effective but is often not well tolerated, leading to low adherence rates in many patients. Bariatric surgery has been approved as treatment for OSA in patients with co-morbid obesity and in small studies, appears to produce substantial improvements. However, no trials directly comparing bariatric procedures with standard CPAP treatment yet exist to guide clinicians and patients in choosing the most appropriate first line treatment. This trial will address the feasibility and safety, and estimate the effect sizes for a subsequent Phase 3 trial. We will recruit 80 patients with severe OSA and morbid obesity (body mass index, BMI, of 35-45 kg/m2) from two large clinical sleep programs that together care for a wide spectrum and demographically diverse group of OSA patients. After establishing patient and physician equipoise, subjects will be randomized to a trial of CPAP or laparoscopic gastric banding as first line treatment for OSA. The primary outcome measures will be improvement in OSA severity under both ideal and real life conditions (i.e., in the CPAP arm, while using CPAP in a controlled environment vs. while using prescribed therapy in the usual home environment, respectively), which will allow for assessments of both comparative efficacy and effectiveness. Outcomes will be assessed at 9 months to quantify the early effectiveness of each treatment strategy as well as to demonstrate clinical equipoise in conducting a future larger long term trial using these two arms. Further follow-up will occur at 18 months in a subset of 40 patients to determine effect sizes for the subsequent study at a point where the bariatric arm has neared a plateau in weight. Secondary outcomes will include patient-related outcomes including sleepiness, quality of life, and an index of health service utilization. In addition, changes in biomarkers related to inflammation, insulin resistance, lipids, blood pressure, and arterial stiffness will be assessed in each group, and in relationship to changes in BMI and OSA, to identify promising outcome measures for future trials. Incurred costs will be collected in all subjects in order to establish the parameters needed for a cost effectiveness analysis. This pilot study will represent the first controlled comparison of medical and surgical treatments for OSA and in addition, will provide the necessary data to develop the optimal study design for a subsequent long term multi-center comparative effectiveness study to better understand the potential role that bariatric surgery may offer in the management of OSA.
Atopic Dermatitis (AD) is the most common inflammatory skin disease, affecting about 17% of children and 6% adults in the USA , . AD is characterized by skin barrier disruption, an aberrant adaptive immune response (i.e., Th2 polarized) to environmental allergens, susceptibility to cutaneous bacterial infections and intractable itch , . The intense pruritus and cutaneous infections contribute to the morbidity of AD and are major drivers of the reduced quality-of-life associated with this disease , . In the World Health Organization 2010 Global Burden of Disease survey, AD has ranked first among common skin diseases . So far, AD treatments have targeted inflammation with the widespread use of topical and more intermittent use of systemic corticosteroids. In summary, despite its high prevalence, effects on quality-of-life and economic burden - there are few effective treatments for AD.

Doxycycline are tetracycline antibiotics broadly used systemically to treat inflammatory-dermatologic conditions. Several studies in human and animal models have shown doxycycline have anti-inflammatory and pro-healing properties, mainly by blocking tissue proteolytic activity. Doxycycline have been reported to nonselectively inhibit members of the metalloproteinases (MMP) superfamily \[reviewed in , \]. In addition to this direct inhibitory activity, doxycycline indirectly prevents tryptic kallikreins activation by MMPs . Growing body of evidence suggests that the tetracycline might also directly downregulate Protease Activator receptor (PAR)-2 expression and function, which was also found to play a role in induction of local inflammatory mediators . Importantly, the doxycycline antimicrobial activity could lead to reduced Staphylococcus infection/colonization in AD skin, a known trigger of AD flares
BACKGROUND: Hematoma volume is a major pathophysiological hallmark of acute intracerebral hemorrhage (ICH). We investigated how the variance in functional outcome induced by the ICH volume is explained by neurological deficits at admission using a mediation model.
METHODS: Patients with acute ICH treated in three tertiary stroke centers between January 2010 and April 2019 were retrospectively analyzed. Mediation analysis was performed to investigate the effect of ICH volume (0.8 ml (5% quantile) versus 130.6 ml (95% quantile)) on the risk of unfavorable functional outcome at discharge defined as modified Rankin Score (mRS) ≥ 3 with mediation through National Institutes of Health Stroke Scale (NIHSS) at admission. Multivariable regression was conducted to identify factors related to neurological improvement and deterioration.
RESULTS: Three hundred thirty-eight patients were analyzed. One hundred twenty-one patients (36%) achieved mRS ≤ 3 at discharge. Mediation analysis showed that NIHSS on admission explained 30% [13%; 58%] of the ICH volume-induced variance in functional outcome at smaller ICH volume levels, and 14% [4%; 46%] at larger ICH volume levels. Higher ICH volume at admission and brainstem or intraventricular location of ICH were associated with neurological deterioration, while younger age, normotension, lower ICH volumes, and lobar location of ICH were predictors for neurological improvement.
CONCLUSION: NIHSS at admission reflects 14% of the functional outcome at discharge for larger hematoma volumes and 30% for smaller hematoma volumes. These results underscore the importance of effects not reflected in NIHSS admission for the outcome of ICH patients such as secondary brain injury and early rehabilitation.
<P>PROBLEM TO BE SOLVED: To obtain a dental embedding material improved in its compressive strength after calination in a suitable range, while keeping characteristics specific to a gypsum-based embedding material.  <P>SOLUTION: This dental embedding material is obtained by adding an auxiliary material for increasing the compressive strength after calcination to a main material consisting mainly of a gypsum component and a silica component. At least one kind of compound selected from the group consisting of an alkali metal chloride, an alkaline earth metal chloride, and an alkaline earth metal fluoride is used as the auxiliary material, and added to the main material in amount of 0.01-0.3 pts.wt. based on 100 pts.wt. of the main material. When sodium chloride is used as the auxiliary material, the sodium chloride is added to the main material in an amount of 0.02-0.2 pts.wt. based on 100 pts.wt. of the main material. When calcium chloride is used as the auxiliary material, the calcium chloride is added to the main material in an amount of 0.03-0.1 pts.wt. based on 100 pts.wt. of the main material.  <P>COPYRIGHT: (C)2004,JPO
BACKGROUND: In persons with cystic fibrosis (pwCF), little is known about the prevalence or impact of HPV on quality of life and attitudes towards vaccination.
METHODS: We conducted a national online survey of adult pwCF. We sought to determine the prevalence of self-reported HPV infection, disease-associated complications and effects on quality of life. Additionally, we investigated factors associated with vaccination status.
RESULTS: A total of 235 adult pwCF across Canada (≥18 years, 68% female) completed the survey. Forty-eight percent of female pwCF had a history of abnormal Pap smear, with 62% self-reporting a 'no' or 'low' chance of risk of HPV-associated disease. Across participants, 12% reported at least one HPV-associated complication including anogenital warts (58%), HPV-associated malignancies (34%) and cervical dysplasia requiring colposcopy (69%). Only 19% reported discussions with their CF care provider around HPV complications. Across both sexes, pwCF experienced high psychosocial burden in the domains of 'worries and concerns', 'sexual impact' and 'self-image'. Sixty percent of adult pwCF were unvaccinated for HPV. Eighty-one percent reported never having discussed HPV vaccination with their CF care provider, with similar rates in vaccinated and unvaccinated groups. Barriers to vaccination included: lack of discussions with healthcare providers (31%), insured coverage (based on age) (19%) and perceived side effects/risk (10%).
CONCLUSIONS: Across adult pwCF, we found high prevalence of HPV disease and associated HPV-psychosocial burden and low vaccination uptake. Given the limited medical discussions reported, incorporation of HPV prevention and management should be prioritized by CF care providers as part of comprehensive multimodal care.
A chlorhexidine gluconate-isopropyl alcohol wet wipe product includes a disinfecting solution, a nonwoven fabric and an outer pack. The disinfecting solution further contains chlorhexidine gluconate and purified water. The nonwoven fabric is configured to be impregnated with the disinfecting solution. The outer pack is configured to wrap the chlorhexidine gluconate-isopropyl alcohol wet wipe product and is a multilayer laminated film pack. The disinfecting solution also includes isopropyl alcohol. The disinfecting effect of the disinfecting wet wipe is greatly improved, the stability of the active ingredients in the disinfecting wet wipe is maintained, the effective period is prolonged, and the contents of chlorhexidine gluconate and isopropyl alcohol in the wet wipe solution in the product that act on the consumer's skin surface is consistent with the labeled amounts and achieve sufficient contents of active ingredients.
The application discloses NIPSNAP2 as a cardiac hypertrophy biomarker and application thereof. The examples disclose the use of NIPSNAP2 as a biomarker or as a drug target substance in peripheral blood and/or myocardial tissue in the preparation of a product. The examples disclose the use of substances that enhance the activity and/or the expression level of NIPSNAP2 in peripheral blood and/or myocardial tissue. The embodiment discloses application of mice with enhanced NIPSNAP2 activity and/or expression level in peripheral blood and/or myocardial tissue in preparation and/or screening of medicines. The examples disclose agonists that up-regulate the expression of the NIPSNAP2 gene and over-express the NIPSNAP2 gene. The examples disclose kits comprising detection of NIPSNAP2 activity and/or expression level.
Deep learning methods and systems for detecting biomarkers within optical coherence tomography volumes using such deep learning methods and systems are provided. Embodiments predict the presence or absence of clinically useful biomarkers in OCT images using deep neural networks. The lack of available training data for canonical deep learning approaches is overcome in embodiments by leveraging a large external dataset consisting of foveal scans using transfer learning. Embodiments represent the three-dimensional OCT volume by “tiling” each slice into a single two dimensional image, and adding an additional component to encourage the network to consider local spatial structure. Methods and systems, according to embodiments are able to identify the presence or absence of AMD-related biomarkers on par with clinicians. Beyond identifying biomarkers, additional models could be trained, according to embodiments, to predict the progression of these biomarkers over time.